FDA requires 1-year natural history group and P3 single arm study, Michael Taylor notes

FDA requires 1-year natural history group and P3 single arm study, Michael Taylor notes
FDA seen positive for BNTC timeline

Michael Taylor, co-founder / portfolio manager at Agora Trading, outlines his positive interpretation of recent FDA meeting minutes regarding BNTC.

He highlights that the FDA has requested a one-year natural history control group, a Phase 3 single arm study, and a six-month interim endpoint. Taylor expects the study to enroll very quickly, with a readout anticipated in the second half of 2027 at six months.

Taylor recently highlighted AQRT's planned Phase 2 Vitiligo study, which aims to double the company’s total addressable market to $1 billion in the fourth quarter of 2026 (link). He also covered a $2 billion preferred convertible agreement between Summit Therapeutics and AstraZeneca to advance lung cancer therapies (link). These previous updates reflect Taylor's continued focus on clinical study progress and major biopharma deals.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.